Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations i...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nature reviews cardiology Ročník 19; číslo 7; s. 475 - 495
Hlavní autori: Gorog, Diana A, Storey, Robert F, Gurbel, Paul A, Tantry, Udaya S, Berger, Jeffrey S, Chan, Mark Y, Duerschmied, Daniel, Smyth, Susan S, Parker, William A E, Ajjan, Ramzi A, Vilahur, Gemma, Badimon, Lina, Berg, Jurrien M Ten, Cate, Hugo Ten, Peyvandi, Flora, Wang, Taia T, Becker, Richard C
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Nature Publishing Group 01.07.2022
Predmet:
Biomarkers
Coronaviruses
COVID-19
COVID-19 - complications
Humans
Mortality
Pandemics
SARS-CoV-2
Thrombosis
Thrombosis - diagnosis
Thrombosis - etiology
ISSN:1759-5002, 1759-5010, 1759-5010
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and D-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1759-5002
1759-5010
1759-5010
DOI:10.1038/s41569-021-00665-7